LINC01259

Across TCGA pan-cancer cohorts, LINC01259 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of LINC01259’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LINC01259 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01259 is over-expressed in tumor, although a few such as LUSC and COAD show the opposite, repressed pattern.

KIRC, LUSC, and STAD are the cancer types where LINC01259 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01259 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.026	.002	5	view →
LUSC	Female	All	−0.162	.015	2	view →
STAD	All	All	+0.099	.024	2	view →
COAD	Female	All	−0.050	.020	2	view →
BRCA	All	All	+0.030	.023	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

LINC01259–KIRC

Open the KIRC breakdown →